Manufacturer: Dragon Pharma
Pharmaceutical name: Tesamorelin
Pack: 1 vial (5 mg)
Tesamorelin (Tesamorelin) is formulated with growth hormone-releasing factor (GRF).
Tesamorelin is utilized to minimize excess abdominal fat that arises from certain HIV medications. This condition is known as lipodystrophy (LYE-poe-DIS-troe-fee).
Tesamorelin is not intended for weight loss and should not be prescribed for obesity treatment.
Tesamorelin (Tesamorelin for injection) is specifically indicated for the reduction of excess abdominal fat in HIV-positive patients experiencing lipodystrophy.
Limitations of Use:
Given that the long-term cardiovascular safety and potential benefits of Tesamorelin treatment have not been studied or established, careful evaluation should be undertaken regarding the continuation of Tesamorelin treatment in patients who do not demonstrate a clear efficacy response based on the reduction of visceral adipose tissue, evaluated by waist circumference or CT scan.
Tesamorelin is not meant for weight management (it has a weight-neutral effect).
No evidence supports improved compliance with anti-retroviral therapies in HIV-positive patients who are using Tesamorelin.
General Dosing Information
The advised dosage of Tesamorelin is 2 mg, administered subcutaneously once daily.
The preferred injection site is the abdomen, and injection sites should be rotated across different areas. Avoid injecting into scar tissue, bruises, or the navel.
Reconstitution Procedure
Tesamorelin must be reconstituted with the diluent included with the product.
To reconstitute the 2 mg vial of Tesamorelin, add 2.1 mL of diluent. Mix gently by rolling the vial in your hands for 30 seconds. Do not shake.
For detailed instructions on reconstituting Tesamorelin, refer to the INSTRUCTIONS FOR USE leaflet included in the boxes containing the Tesamorelin and diluent.
Administer Tesamorelin immediately after reconstitution, and dispose of any unused solution. If not used right away, the reconstituted Tesamorelin solution should be discarded. Do not freeze or refrigerate the reconstituted solution.
Administration
The reconstituted Tesamorelin solution should always be visually inspected for particulate matter and discoloration before administration, whenever the solution and container allow. Tesamorelin should only be injected if the solution is clear, colorless, and free of particulate matter.
Tesamorelin should be administered subcutaneously into the skin of the abdomen, with injection sites rotated to different areas. Avoid injecting into scar tissue, bruises, or the navel.